about
Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIVAccumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria.Impact of inactive empiric antimicrobial therapy on inpatient mortality and length of stay.Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trialAbacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.Optimizing treatment switch for virologic failure during first-line antiretroviral therapy in resource-limited settings.Elevated plasma concentrations of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in patients coinfected with human immunodeficiency virus and hepatitis B or C: case series and literature review.Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral TherapyUnintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 WeeksSuboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines.Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project.Empiric antibiotic selection for infectious emergencies: bacterial pneumonia, meningitis and sepsis.Point-of-care testing for infectious diseases: opportunities, barriers, and considerations in community pharmacy.Impact of an electronic medical record on the incidence of antiretroviral prescription errors and HIV pharmacist reconciliation on error correction among hospitalized HIV-infected patients.Antiretroviral Pharmacokinetics in Pregnant Women.Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines.The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.Dosing nucleoside reverse transcriptase inhibitors in adults receiving continuous veno-venous hemofiltration.Pharmacist-provided rapid HIV testing in two community pharmacies.Consumer interest in community pharmacy HIV screening services.Clinical implications of antiretroviral drug interactions with warfarin: a case-control study.Lack of effect of fluoroquinolone resistance on mortality in subjects with Pseudomonas aeruginosa bacteraemia.Breakthrough Candida infections in patients receiving voriconazole.Plasma and Intracellular Pharmacokinetics of Tenofovir in Patients Switched from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide.Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART.Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients.Low incidence of renal impairment observed in tenofovir-treated patients.Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma.A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction.Adjustment of Antimicrobial Dosages for Continuous Venovenous Hemofiltration Based on Patient-Specific InformationEffect of on-call infectious-diseases pharmacists on antibiotic expendituresMidwest pharmacists' familiarity, experience, and willingness to provide pre-exposure prophylaxis (PrEP) for HIVThe use of ACE inhibitors as renoprotective agents in Medicaid patients with diabetesClinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated ReviewLow Rate of Sex-specific Analyses in Presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) Meeting, 2018: Room to ImproveEffect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ARTA pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda
P50
Q34538556-58CF10E8-2CD2-485C-AFD4-0E548DBA0637Q34998736-D3FDC4AC-E646-4A1D-8354-F20249399E1DQ35091494-4A30E605-955F-4342-81DC-61427763644CQ35215604-08FA17CD-311F-44C6-8AF6-9CB677BC12A5Q35233168-E13E0CDB-D0C7-498C-95B8-FF637E61C02DQ36157484-76C8887B-8E6B-4062-80F3-89094AA6792DQ36277913-C4BCB2F3-14ED-4D74-8B84-486421752C39Q36290691-1851C0F9-7EDA-405A-8225-A38FB30D9309Q36635690-AB791A8F-6073-461C-834B-0701FD999070Q36676527-785BC3E8-AD20-46E1-8B40-616215D442E2Q36763160-B9494FF7-1549-4B28-A338-76D4CFFE726CQ37399082-3E6FE96C-C7F9-4BD2-876E-2238C2986DCEQ37544281-9F66A62A-5055-4CBA-9F27-8F7FA6B08166Q38196286-C3DCE400-1837-4BDE-96FF-F67575B12781Q38308187-72B2B4F6-CEB6-461F-A199-FF8867F76DB0Q38571596-36F23898-10CF-49D1-B23F-372321A2C944Q38686382-70C0FB93-EFE6-4D5E-B423-1615BE135DE5Q38771869-E4EAEDEF-AA93-4A14-A088-216CA4DDFF29Q38851258-272F5550-A858-46CA-BC4D-F52F1EE4D8F0Q38868949-099565BA-8F24-4DFD-A5E0-41BD87FCC2FFQ39037792-E84177CE-9DFE-4CA1-A84A-70081C07BAE6Q41653355-A3131336-A812-4F17-BB4B-A5F14EB9878AQ41653470-7E4CB294-6B6D-4239-A439-29B78F0BA8FEQ44415557-A6E4B0BF-2DDF-49A4-8B7F-5D3E6A606C34Q46499245-3F61DF67-5F54-43AD-B270-EAF7198180F8Q46508204-5201805F-35A1-40EA-ACC4-44AE036E5395Q48506430-545ED3F7-26BD-4EE8-9A8E-E8C3A9DDF7E9Q48524975-4024E361-CE80-42C4-81C4-6BB9A70300DAQ50438363-EC37DD57-50A5-4C0F-A373-B78B3FAC6FC8Q51050331-29DFB9B2-0737-4954-83E7-5B2451839ACBQ54248327-50407DC6-A4EA-4594-8D94-AA3B3DA4A552Q55475404-7806FF62-8C02-4201-AA44-567A1D1EF527Q57779827-B3826CFA-636F-482A-86D0-665FD3C29EDAQ57779862-369D105C-F293-4CB2-A253-8E4DC6AB908FQ59807562-4207F329-6696-4EDF-94AD-B57596960E40Q74299418-5556BBE1-508B-42E4-A594-FCE03582BE0FQ91073756-F7A39B72-EE16-40B6-A288-687924D3A858Q91508395-8D453077-662D-4CE2-8000-5FB92EA02944Q91828901-C70C1881-D965-4194-9B49-431CCB1CCFF8Q91884331-D2427BD7-9D1D-47F3-BC44-E43D0633C30B
P50
description
researcher
@en
name
K K Scarsi
@en
K K Scarsi
@nl
type
label
K K Scarsi
@en
K K Scarsi
@nl
prefLabel
K K Scarsi
@en
K K Scarsi
@nl
P106
P31
P496
0000-0001-9406-693X